Biopharmaceutical company MediciNova, Inc. recently announced in a press release that the initial results of an ongoing clinical trial for the drug MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS) were presented by the study’s principal investigator Dr. Benjamin Rix Brooks at the 2015 American Academy of Neurology (AAN)…

In a highly unusual move, last Friday the U.S. Food and Drug Administration (FDA) issued a statement calling on pharmaceutical firm Genervon to release all data pertaining to a recent small study involving the company’s ALS drug candidate GM604. In its statement, the FDA affirms that it…

The ALS Association together with the Harvard Stem Cell Institute, and the Neurological Clinical Research Institute at Massachusetts General Hospital recently announced in a press release a collaboration with GlaxoSmithKline (GSK) in a clinical trial to assess a potential therapy with an anti-epileptic drug in…

Researchers at the University Medical Center of the Johannes Gutenberg-University, Mainz, Germany recently revealed in the journal Scientific Reports the finding that low-frequency magnetic fields do not have a detrimental effect or aggravate the development of neurodegenerative diseases such as ALS in mice. The study…

Researchers from the Institute of Pathobiochemistry at the Medical Center of Johannes Gutenberg University Mainz, Germany, have recently released results from a study in which they used animal experiments to assess the possibility that low-frequency alternating magnetic fields (LFMF), such as those generated by overhead power lines, are a…

A study published in the latest edition of Nature Immunology presents evidence that a key protein associated with Amyotrophic lateral sclerosis (ALS) also plays an important role in a patient’s immune response to viral infections.  The study entitled, “Senataxin suppresses the antiviral transcriptional…

A new study on amyotrophic lateral sclerosis (ALS) provided evidence that certain areas of gray matter (GM) are disproportionately and asymmetrically vulnerable to the pathology of ALS. The study entitled “Exposing asymmetric gray matter vulnerability in amyotrophic lateral sclerosis” was published on the…

The Muscular Dystrophy Association (MDA) continues to enhance its research and healthcare services programs and has recently hired two new Scientific Program Officers: Amanda Haidet-Phillips and Laura Hagerty, both Ph.D. They will be reporting to Grace Pavlath, also Ph.D, who joined MDA in the past year to be the Scientific Program Director…

A clinical trial led by Dr. Marta Kaminska from the McGill University Health Center in Canada is currently recruiting participants to enroll in a study to assess the use of non-invasive home ventilation by patients with amyotrophic lateral sclerosis (ALS) using the iVAPS mode. The study is entitled…

A recent study assessed the association between individual prescription compounds and amyotrophic lateral sclerosis (ALS) risk in a population-based study in Taiwan. The study entitled “Aspirin use associated with amyotrophic lateral sclerosis: a total population-based case-control study” was published in the Journal of…